Differential beta-catenin expression between glottic and supraglottic laryngeal carcinoma.
Glottic carcinomas present with a favorable prognosis comparing to supraglottic. This fact is mainly attributed to differences in anatomical, histological and embryological aspects. It is possible that differential molecular anatomy between the two distinct anatomical entities contributes to this clinical observation as well. The current study intended to evaluate, by immunohistochemistry in paraffin-embedded tissue samples from 97 invasive squamous laryngeal carcinomas, the possible differential expression of crucial molecules for malignant cell's function such as integrin-linked kinase, phosphorylated Akt, E-cadherin, beta-catenin, androgen receptor, estrogen receptor-beta and vimentin between glottic and supraglottic laryngeal carcinomas. We documented a correlation of supraglottic laryngeal carcinomas with high grade (p = 0.001) and enhanced tumor TNM stage (p < 0.001). The supraglottic location was correlated with the abolishment of beta-catenin from the membrane (p = 0.025). However, the diverse anatomical locations are not characterized by statistically significant differential expression of ILK, p-Akt, AR, ER-beta, E-cadherin and vimentin. Our results show that it is possible that molecular factors, such as beta-catenin, are differently expressed in glottic and supraglottic carcinomas, leading to the distinct clinical behavior of those tumors.
Goulioumis
Anastasios K
AK
Anatomy Department, Medical School, University of Patras, Patras, Greece. goulioum@upatras.gr
Varakis
John
J
Goumas
Panos
P
Papadaki
Helen
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D051176:beta Catenin / Q000378:metabolism*
D051176:beta Catenin
Acta Otorrinolaringol Esp. 2007 Dec;58(10):449-53
18082073
J Cell Biochem. 2000 Apr;78(1):141-50
10797573
Am J Otolaryngol. 1998 Mar-Apr;19(2):83-8
9550437
Cell Signal. 2002 May;14(5):381-95
11882383
Cells Tissues Organs. 2005;179(1-2):56-65
15942193
Neoplasma. 1999;46(1):66-71
10355537
Acta Otolaryngol. 1999;119(7):847-51
10687946
Cancer. 2008 May 1;112(9):2088-100
18327819
J Clin Epidemiol. 1989;42(8):755-8
2788212
Virchows Arch. 2008 Nov;453(5):511-9
18813944
Int J Cancer. 2004 Dec 20;112(6):1065-71
15386361
Trends Cell Biol. 1999 Aug;9(8):319-23
10407411
Oncol Rep. 2009 Nov;22(5):1063-8
19787222
Nucl Recept Signal. 2008 Feb 01;6:e001
18301781
Arch Otolaryngol Head Neck Surg. 1991 Jul;117(7):774-8
1863444
Pathology. 2007 Jun;39(3):305-18
17558857
Eur Arch Otorhinolaryngol. 2008 Jan;265(1):79-84
17909831
Eur J Cancer. 2002 Sep;38(13):1717-23
12175687
Otolaryngol Head Neck Surg. 1986 Apr;94(4):512-7
3086815
Cancer Res. 2004 Aug 15;64(16):5683-92
15313908
Biochim Biophys Acta. 2004 Apr 1;1691(1):1-15
15053919
Nat Rev Cancer. 2005 Jan;5(1):51-63
15630415
Virchows Arch. 2004 May;444(5):439-46
15045586
J Laryngol Otol. 2006 Dec;120(12):1042-8
16995968
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4374-9
9539744
Otolaryngol Head Neck Surg. 2004 Jan;130(1):89-93
14726916
Arch Otolaryngol Head Neck Surg. 2007 Feb;133(2):145-50
17309983